Psoriasis Mandate Results Released to Mark World Psoriasis Day

Informations

• Publié par: janssen-emea
• Nombre de lectures: 14
• Langue: English

Extrait

Psoriasis Mandate Results Released to Mark World Psoriasis Day

PR Newswire BEERSE, Belgium, October 29, 2012

BEERSE, Belgium,October 29, 2012/PRNewswire/ --

Pledge Your Support Today to Help Drive Much-needed Change for People With Psoriasis

Promising interim results from the Psoriasis Mandate have been released today to markWorld Psoriasis Day. To date 1145 people across 40 European countries have pledged their support for five basic rights of people with psoriasis, but experts are urging people to keep signing the Mandate to drive much-needed improved standards of care.

To view the Multimedia News Release, please click:http://www.multivu.com/mnr/53825-world-psoriasis-day

Professor Matthias Augustin, University Medical Center of Hamburg, Germany, and Chair of the European Expert [1],[2],[3] Working Group for Healthcare in Psoriasis (EEWGHP) says "Psoriasis affects approximately 14 million people across Europe and there is significant variation in the standard of care people receive. Great steps are being made in the management of psoriasis, but lack of awareness and understanding of the condition by policy- makers and the general public adds to the distressing stigmatisation of this disease. The Psoriasis Mandate is our opportunity to give a voice to people living with psoriasis; to help them demand the high quality care that they deserve - please sign it."

The Psoriasis Mandate launched earlier this year by the EEWGHP, Janssen* and The European Umbrella Organisation for Psoriasis Movements (EUROPSO) to provide an opportunity for the community at large, people with psoriasis and their healthcare professionals to pledge their support for achieving the best care possible for those living with psoriasis. Anyone can sign the Psoriasis Mandate (http://www.psoriasis360.com/psoriasis- mandate) to show their support for five key rights of people with psoriasis:

Early and accurate diagnosis Access to a specialist for regular treatment review Access to effective treatment options Involvement and choice in a treatment plan with defined goals Understanding and support from society to live a normal life

To date, 18% of people who have signed the Psoriasis Mandate have psoriasis, 19% have family members or friends across Europe with psoriasis, 21% are healthcare professionals, and 42% of signatures are from members of the public who simply support the cause, demonstrating the growing support and understanding of the need to help people living with this debilitating condition.

The Psoriasis Mandate followed the publication of the first-ever Psoriasis White Paper inJuly 2012by the [4] EEWGHP, whose principle aim is to improve clinical outcomes and quality of life for the 14 million people living [1],[2],[3] with psoriasis in Europe. The White Paper addresses the under-treatment of psoriasis inEurope and provides a framework for action. It calls on healthcare organisations, healthcare professionals, European regulatory bodies, governments, industry, academia and patient advocacy groups to act together implement change. The Psoriasis White Paper is available free of charge via a special feature page on the Journal of the European Academy of Dermatology and Venereology (JEADV) website (http://onlinelibrary.wiley.com/doi/10.1111/j.1468- 3083.2012.04576.x/full).

Mr. Ottfrid Hillmann, President of EUROPSO, says "For too long now psoriasis has been a low priority. These days it is possible for people with psoriasis to live a normal life, but that can only be achieved through early access to high quality care. We continue to call on all people involved in the management of psoriasis, including healthcare professionals, people with psoriasis, their families, and governments, to pledge their support to improve care across Europe. We are all working towards a brighter future for those with psoriasis, but this will only be achieved with a unified approach."

About Psoriasis

Psoriasis is a chronic disease caused when the immune system mistakenly attacks healthy skin cells, speeding up [5] [6] skin cell production. Plaque psoriasis, the most common type of psoriasis, often results in patches of thick, red or inflamed skin covered with silvery scales (known as plaques). These plaques usually itch or feel sore, can crack and bleed, and can occur anywhere on the body. It is often very painful and associated with multiple physical and [7] psychological burdens such as depression.

[1],[2],[3] Psoriasis affects 125 million people worldwide and approximately 14 million people inEurope. The type, symptoms and severity of psoriasis may differ from one person to another, with its effects ranging from mild or moderate, to severe.

Biological therapies are a valuable advancement in the treatment of moderate to severe plaque psoriasis, and long- term efficacy and safety data on available treatment options is vital to support healthcare professionals in their decision-making about the most suitable treatment option for patients.

For more information about psoriasis, available treatment options and tools to assess the medical severity of psoriasis please visit http://www.psoriasis360.com

About Janssen

Janssen Pharmaceutical Companies are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g. multiple myeloma and prostate cancer), immunology (e.g. psoriasis), neuroscience (e.g. schizophrenia, dementia and pain), infectious disease (e.g. HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g. diabetes).

Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by- side with healthcare stakeholders, based on partnerships of trust and transparency. More information can be found athttp://www.janssen-emea.com/.

References

1. Augustin M, Herberger K, Hintzen S et al. Prevalence of skin lesions and need for treatment in a cohort of 90880 workers. Br J Dermatol 2011; 165(4): 865-873 2. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, on behalf of the Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. J Invest Dermatol 2012 Sep 27 [Epub ahead of print] 3. Ortonne JP, Prinz JC. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis. Eur J Dermatol 2004; 14: 41-45 4. Augustin M and The European Expert Working Group for Healthcare in Psoriasis. A framework for improving the quality of care for people with psoriasis.JEADV2012, 26 (Suppl. 4), 1-16 5. The Psoriasis Association. Available at:http://www.psoriasis-association.org.uk/pages/view/about-psoriasisLast accessedOctober 2012 6. The Psoriasis Association. Available athttp://www.psoriasis-association.org.uk/pages/view/about-psoriasis/types-of- psoriasis/plaqueLast accessedOctober 2012 7. Rapp SR, Feldman SR, Exum ML et al. Psoriasis ca uses as much disability as other major medical disease.sJ Am Acad Dermatol1999; 41: 401-407

*Financial assistance for The Psoriasis Mandate and roundtable discussions and writing support for the Psoriasis White Paper was provided by Janssen, more specifically Janssen Pharmaceutica NV, Belgium.

Video:http://www.multivu.com/mnr/53825-world-psoriasis-day